VRPX Biotechnology Penny Stock Post Earnings

NASDAQ:VRPX   Virpax Pharmaceuticals, Inc.
VRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX

beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced

on the potential of future earnings. The short and long-moving averages ratio shows bullish

momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over

the POC line so it is higher than the mean of the share price traded for the duration of the

volume profile. I see this as a risky long setup expectant of a 40% profit based on the target

of the YTD high in February.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.